A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis

Trial Profile

A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top